66 related articles for article (PubMed ID: 29236346)
1. Therapy-related acute myeloid leukaemia and myelodysplastic syndrome in Victoria, Australia 2003-2014.
Ong DM; Farrugia H; Wei A
Intern Med J; 2018 Jul; 48(7):822-829. PubMed ID: 29236346
[TBL] [Abstract][Full Text] [Related]
2. Myelodysplastic syndrome and acute myeloid leukemia after receipt of granulocyte colony-stimulating factors in older patients with non-Hodgkin lymphoma.
Calip GS; Moran KM; Sweiss KI; Patel PR; Wu Z; Adimadhyam S; Lee TA; Ko NY; Quigley JG; Chiu BC
Cancer; 2019 Apr; 125(7):1143-1154. PubMed ID: 30548485
[TBL] [Abstract][Full Text] [Related]
3. Survival difference between secondary and de novo acute myeloid leukemia by age, antecedent cancer types, and chemotherapy receipt.
Sedeta E; Jemal A; Nisotel L; Sung H
Cancer; 2024 Jun; 130(11):1952-1963. PubMed ID: 38244208
[TBL] [Abstract][Full Text] [Related]
4. Cumulative exposure to melphalan chemotherapy and subsequent risk of developing acute myeloid leukemia and myelodysplastic syndromes in patients with multiple myeloma.
Jonsdottir G; Björkholm M; Turesson I; Hultcrantz M; Diamond B; Porwit A; Landgren O; Kristinsson SY
Eur J Haematol; 2021 Aug; 107(2):275-282. PubMed ID: 33966293
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for de novo and therapy-related myelodysplastic syndromes (MDS).
Yarosh R; Roesler MA; Murray T; Cioc A; Hirsch B; Nguyen P; Warlick E; Poynter JN
Cancer Causes Control; 2021 Mar; 32(3):241-250. PubMed ID: 33392905
[TBL] [Abstract][Full Text] [Related]
6. Subsequent primary malignancies after diffuse large B-cell lymphoma in the modern treatment era.
Tao L; Clarke CA; Rosenberg AS; Advani RH; Jonas BA; Flowers CR; Keegan THM
Br J Haematol; 2017 Jul; 178(1):72-80. PubMed ID: 28542862
[TBL] [Abstract][Full Text] [Related]
7. Obesity over the life course and risk of acute myeloid leukemia and myelodysplastic syndromes.
Poynter JN; Richardson M; Blair CK; Roesler MA; Hirsch BA; Nguyen P; Cioc A; Warlick E; Cerhan JR; Ross JA
Cancer Epidemiol; 2016 Feb; 40():134-40. PubMed ID: 26720913
[TBL] [Abstract][Full Text] [Related]
8. Association between meat, fish, and fatty acid intake and incidence of acute myeloid leukemia and myelodysplastic syndrome: the Japan Public Health Center-based Prospective Study.
Shimomura Y; Sobue T; Zha L; Kitamura T; Iwasaki M; Inoue M; Yamaji T; Tsugane S; Sawada N
Environ Health Prev Med; 2023; 28():19. PubMed ID: 36878605
[TBL] [Abstract][Full Text] [Related]
9. Risk of cancer in relatives of patients with myelodysplastic neoplasia and acute leukemias.
Nitschke NJ; Rostgaard K; Andersen MK; Hjalgrim H; Grønbæk K
Cancer Epidemiol; 2024 Feb; 88():102523. PubMed ID: 38198910
[TBL] [Abstract][Full Text] [Related]
10. Second malignancies after multiple myeloma: from 1960s to 2010s.
Thomas A; Mailankody S; Korde N; Kristinsson SY; Turesson I; Landgren O
Blood; 2012 Mar; 119(12):2731-7. PubMed ID: 22310913
[TBL] [Abstract][Full Text] [Related]
11. [Environmental and occupational risk factors for myelodysplastic syndrome].
Garnier R
Bull Cancer; 2023 Nov; 110(11):1116-1128. PubMed ID: 37419729
[TBL] [Abstract][Full Text] [Related]
12. Incidence and Burden of the Myelodysplastic Syndromes.
Cogle CR
Curr Hematol Malig Rep; 2015 Sep; 10(3):272-81. PubMed ID: 26134527
[TBL] [Abstract][Full Text] [Related]
13. Myeloid malignancies in the real-world: Occurrence, progression and survival in the UK's population-based Haematological Malignancy Research Network 2004-15.
Roman E; Smith A; Appleton S; Crouch S; Kelly R; Kinsey S; Cargo C; Patmore R
Cancer Epidemiol; 2016 Jun; 42():186-98. PubMed ID: 27090942
[TBL] [Abstract][Full Text] [Related]
14. Using patient-reported health status to improve prognostic assessment in patients with acute myeloid leukemia: current challenges and future applications.
Efficace F; Lo-Coco F
Haematologica; 2013 Jan; 98(1):7-9. PubMed ID: 23277592
[No Abstract] [Full Text] [Related]
15. Forecasting of Lung Cancer Incident Cases at the Small-Area Level in Victoria, Australia.
Wah W; Stirling RG; Ahern S; Earnest A
Int J Environ Res Public Health; 2021 May; 18(10):. PubMed ID: 34064949
[TBL] [Abstract][Full Text] [Related]
16.
Zhang X
Case Rep Oncol; 2023; 16(1):893-899. PubMed ID: 37900834
[TBL] [Abstract][Full Text] [Related]
17. Treosulfan for acute myeloid leukaemia and myelodysplastic syndrome in adults, and malignant and non-malignant haematological diseases in children.
Aust Prescr; 2023 Jun; 46(1):18-19. PubMed ID: 38053669
[No Abstract] [Full Text] [Related]
18. Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial.
Mittelman M; Platzbecker U; Afanasyev B; Grosicki S; Wong RSM; Anagnostopoulos A; Brenner B; Denzlinger C; Rossi G; Nagler A; Garcia-Delgado R; Portella MSO; Zhu Z; Selleslag D
Lancet Haematol; 2018 Jan; 5(1):e34-e43. PubMed ID: 29241762
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic choices after hypomethylating agent resistance for myelodysplastic syndromes.
Montalban-Bravo G; Garcia-Manero G; Jabbour E
Curr Opin Hematol; 2018 Mar; 25(2):146-153. PubMed ID: 29266015
[TBL] [Abstract][Full Text] [Related]
20. 3q26/EVI1 rearrangement in myelodysplastic/myeloproliferative neoplasms: An early event associated with a poor prognosis.
Hu Z; Hu S; Ji C; Tang Z; Thakral B; Loghavi S; Medeiros LJ; Wang W
Leuk Res; 2018 Feb; 65():25-28. PubMed ID: 29288910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
